Literature DB >> 12395372

E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma.

Wei Sun1, Guillermo A Herrera.   

Abstract

Flat urothelial carcinoma in situ (CIS) is a precursor of invasive transitional cell carcinoma (TCC). High-grade TCCs frequently are accompanied by CIS in surrounding urothelium. In contrast, superficial, noninvasive papillary TCCs are often low grade and generally are unaccompanied by CIS. E-cadherin (E-CD) is a member of a family of transmembrane glycoproteins involved in intercellular adhesion. Loss or decreased expression of E-CD has been linked to the invasive phenotype of a wide variety of human neoplasms, including bladder tumors. The objective of this study was to compare the expression of E-CD in high-grade urothelial dysplasia (HD)/CIS, superficial papillary TCC, benign urothelium, and invasive TCC. Staining for E-CD was performed in formalin-fixed, paraffin-embedded sections using a Ventana NexES immunostainer (Tuscon, AZ). Percentage and intensity of cell membrane staining for E-CD was calculated for the 4 groups using the quantitative Automatic Cellular Imaging System (ChromaVision, San Juan Capistrano, CA). The results were as follows: The CIS group (n = 23) had percentage and intensity (92.8%, 120.0 U) of E-CD expression similar to the superficial noninvasive papillary TCC group (n = 16, 97.8%, 123.0 U) and the benign urothelium group (n = 17, 87.9%, 104.6 U), but it had statistically significant higher percentage and intensity than the invasive TCC group (n = 15, 45.4%, and 39.2 U, P <.05). Our data indicate that CIS and superficial, noninvasive papillary TCCs strongly express E-CD. In contrast, loss of E-CD expression is associated with the invasive TCC phenotype. Only when TCCs become invasive does E-CD expression decrease in directly proportion to the depth of invasion. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12395372     DOI: 10.1053/hupa.2002.127441

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

1.  Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma.

Authors:  Johannes Breyer; Michael Gierth; Sanzhar Shalekenov; Atiqullah Aziz; Julius Schäfer; Maximilian Burger; Stefan Denzinger; Ferdinand Hofstädter; Christian Giedl; Wolfgang Otto
Journal:  World J Urol       Date:  2015-09-22       Impact factor: 4.226

2.  [Use of silicon chip technology to detect protein-based tumor markers in bladder cancer].

Authors:  T Jäger; T Szarvas; F vom Dorp; C Börgermann; M Schenck; K W Schmid; H Rübben
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 3.  [Bladder carcinoma cell lines as models of the pathobiology of bladder cancer. Review of the literature and establishment of a new progression series].

Authors:  J Hatina; W Huckenbeck; H Rieder; H-H Seifert; W A Schulz
Journal:  Urologe A       Date:  2008-06       Impact factor: 0.639

4.  Correlation between the cytology of urine sediment in fresh sample and smears stained by Papanicolaou and Giemsa methods.

Authors:  Luis Alberto Palaoro; Margarita Angerosa
Journal:  J Cytol       Date:  2014-01       Impact factor: 1.000

5.  Expression of E-cadherin, β-catenin, and epithelial membrane antigen does not predict survival in patients with high-risk non-muscle-invasive bladder cancer.

Authors:  Sławomir Poletajew; Łukasz Fus; Tomasz Ilczuk; Piotr Wojcieszak; Małgorzata Sękowska; Wojciech Krajewski; Aleksander Wasiutyński; Barbara Górnicka; Piotr Radziszewski
Journal:  Cent Eur J Immunol       Date:  2018-12-31       Impact factor: 2.085

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.